Navigation Links
Proepithelin encourages cell growth and migration in prostate cancer
Date:2/26/2009

(PHILADELPHIA) Researchers from Thomas Jefferson University have identified a protein that appears to play a significant role in the growth and migration of prostate cancer cells, especially androgen-independent prostate cancer cells. The study was published in the American Journal of Pathology.

They also found that prostate cancer cells express more of the protein when compared to normal prostate cells, according to Andrea Morrione, Ph.D., an associate professor and director of Urology Research for the Kimmel Cancer Center at Jefferson.

Dr. Morrione conducted the study with Leonard Gomella, M.D., chairman of the department of Urology, Raffaele Baffa, M.D., an associate professor in the department of Urology, and Renato V. Iozzo, M.D., Ph.D., professor in the department of Pathology, Anatomy and Cell Biology.

Proepithelin is a growth factor that promotes cell cycle progression and cell growth in many cellular systems. According to Dr. Morrione, the overexpression of proepithelin by prostate cancer cells may prove to be a useful clinical marker to diagnose prostate cancer.

The presence of proepithelin also encourages cell migration, which is necessary for tumor metastasis. Thus, it may serve as a marker for metastasis.

Proepithelin has previously been shown to play a role in the formation of bladder cancer, and its overexpression is related to an aggressive form of breast cancer according to Dr. Morrione. It also has been shown to play a role in many other cancers, including glioblastomas, multiple myeloma, renal cell carcinoma, gastric cancer and ovarian cancer.

"There are two possible implications of our findings," Dr. Morrione said. "First, proepithelin could be a therapeutic target since it is overexpressed in prostate cancers.

Second, the overexpression of proepithelin could serve as a biomarker and be a diagnostic tool for prostate cancer."

Although localized prostate cancers are potentially curable by surgery and/or radiation therapy, there is no uniform effective treatment for hormone-refractory prostate cancer. There are no reliable prognostic markers to identify which of patients are likely to progress to metastatic disease.

Results of this study will also be presented at the 2009 ASCO Genitourinary Cancers Symposium.


'/>"/>

Contact: Emily Shafer
emily.shafer@jefferson.edu
215-955-5291
Thomas Jefferson University
Source:Eurekalert

Related medicine news :

1. GIVE IT A REST: Delta Dental of Illinois Encourages Routine Dental Exams to Help Detect Nighttime Teeth Grinding
2. Grammy-nominated Singer Angie Stone Encourages African-Americans in Birmingham to Fearlessly FACE Diabetes
3. "12 Days of UNICEF" Encourages Americans to Give Gifts that Give Back This Holiday Season
4. The American Lung Association of the Central States Encourages Kansas City Residents to See Themselves Among the Many Faces of Influenza
5. The American Lung Association of Ohio Encourages Cleveland Residents to See Themselves Among The Many Faces of Influenza
6. NCPA Encourages Member Pharmacists to Consider Refraining From Selling Tobacco Products
7. Combined Insurance Encourages Consumers to Assess Insurance Plans and Protection During Lung Cancer Awareness Month
8. McDonalds(R) Encourages Kids to Take One Minute to Move It
9. Philips Norelco Encourages Americans to Change the Face of Mens Health: Grow a Moustache This November and Raise Awareness for Prostate Cancer Research
10. Suze Orman Joins got milk? Milk Mustache Campaign: New Ad Encourages Families To Invest in Milks Nutritional Assets
11. Combined Insurance Encourages Women to Assess Insurance Plans and Protection During Breast Cancer Awareness Month
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... ... , ... SC&H Group, a leading audit, tax, and consulting firm, announced that ... Services practice . Rossi is the third technology consulting leader to join SC&H Group’s ... and the practice continues to expand.     , Bringing more than 25 years of business ...
(Date:1/17/2017)... ... January 17, 2017 , ... Physicians Education Review®, LCC ... keynote speaker for the 34th Annual Miami Breast Cancer Conference®, on March 9-12, ... president, Phil Talamo, said, “We are delighted to have Sandra Lee join us ...
(Date:1/17/2017)... ... ... make New Year’s resolutions or renew their commitment to better health with the start of ... want to kick off 2017 with better smiles. Dr. Mondavi is offering several promotions for ... , , A new patient package for just $49, which can ...
(Date:1/16/2017)... Boston, MA (PRWEB) , ... January 17, 2017 ... ... winter season, Au Bon Pain, an internationally recognized leader in the fast-casual category, ... new items such as the Good Egg Breakfast Sandwich, Turkey Mash-Up Sandwich, Cranberry ...
(Date:1/16/2017)... ... 2017 , ... Gym Source, America’s leading retailer of premium residential and commercial ... Jersey. , “We are elated to be opening this new showroom,” explains Tom Richard, ... give clients a seamless and motivating shopping experience.” , Every fitness journey is unique, ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... NEW YORK , Jan. 17, 2017 ... USD 8.02 billion by 2021 from USD 6.35 billion ... major factors driving the growth of this market are ... increasing demand for minimally invasive surgeries. The ... type, procedure, application, and region. On the basis of ...
(Date:1/17/2017)... , Jan. 17, 2017  Jazz Pharmaceuticals plc (Nasdaq: ... patient has been enrolled in a Phase 3 clinical ... best supportive care (BSC) in the prevention of hepatic ... hematopoietic stem cell transplant (HSCT) who are at high ... The defibrotide clinical trial will be conducted across approximately ...
(Date:1/17/2017)... 17, 2017  Market Research Future published a Half Cooked Research ... expected to reach USD 33.6 million during the period 2016 to ... ... Devices Market has been examined as a swiftly growing market and ... demand for endoscopy device in various regions.  The increasing growth in ...
Breaking Medicine Technology: